NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin
about
NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.NO-donating aspirin inhibits the activation of NF-kappaB in human cancer cell lines and Min mice.Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells.Modulation of carcinogen metabolism by nitric oxide-aspirin 2 is associated with suppression of DNA damage and DNA adduct formation.Role of chemoprophylaxis with either NSAIDs or statins in patients with Barrett's esophagus.
P2860
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@ast
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@en
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@nl
type
label
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@ast
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@en
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@nl
prefLabel
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@ast
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@en
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@nl
P2093
P1476
NO-releasing aspirin exerts st ...... cells than traditional aspirin
@en
P2093
P407
P478
57 Suppl 12
P577
2006-12-01T00:00:00Z